Introduction: The classic role of vitamin D is its effect on calcium and phosphate homeostasis. The subject of interest in recent years has been its non-calcemic impact on neoplastic processes and the immune system. The aim of the study was to assess 25(OH)D3 concentrations in patients treated for papillary thyroid carcinoma (PTC) and Hashimoto's thyroiditis (HT).
Material: The study included 80 patients aged 19-83 years (average age 52.96 years) treated between 2000-2011 in Swietokrzyskie Centrum Onkologii. The analysis was conducted in two groups of patients: a PTC group of 40 women aged 19 to 83 years (average age 50.40 years) and a HT group of 40 women aged 30 to 75 years (average age 55.73 years). The group of PTC patients was further divided into two subgroups: 19 patients with micro. carcinoma (T1a) and 21 patients with a higher grade of cancer (>T1a). A group of patients with HT comprised women treated with subsitutive doses of L-thyroxine for hypothyroidism. The serum concentration of 25(OH)D3 was compared in both groups: PTC vs. HT. Among patients with PTC serum 25(OH)D3 was analysed depending on the concentration of TSH: TSH< or = 0.1 microlU/ml vs. TSH> 0.1 microlU/ml, and depending on the stage of cancer: Tla vs.> T1a.
Results: There were no differences in the prevalence of hypovitaminosis and vitamin D deficiency in both groups (65% of patients with PTC vs. 62.5% with HT). In the PTC group no statistically significant differences in serum 25(OH)3, depending on the con. centration of TSH and cancer clinical stage, were found.
Conclusion: This study showed no difference in concentrations of 25(OH)D3 in patients with papillary thyroid cancer and Hashimoto's thy. roiditis. Patients with PTC showed no relationship between serum 25(OH)D3 and clinical stage of the disease or TSH.level.